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Searches identiﬁed 14 studies investigating effects of reducing cigarette consumption on lung cancer,
CVD, COPD or FEV1 decline. Three were case-control studies, six cohort studies, and ﬁve follow-up studies
of FEV1. Six studies consistently reported lower lung cancer risk in reducers. Compared to non-reducers,
meta-analysis (random-effects) showed signiﬁcantly lower risk (RR 0.81, 95% CI 0.74–0.88 for any reduc-
tion, and RR 0.78, 0.66–0.92 for the greatest reduction), with no between-study heterogeneity. Four
cohort studies presented CVD results, the combined RR for any reduction being a non-signiﬁcant 0.93
(0.84–1.03). An effect of reduction was not consistently seen for COPD or FEV1 decline. Four cohort stud-
ies presented all-cause mortality results, the combined RR of 0.92 (0.85–1.01) being non-signiﬁcant. The
RR of 0.95 (0.88–1.02) for total smoking-related cancer, from three studies, was also non-signiﬁcant. The
evidence has various weaknesses; few studies, few cases in reducers in some studies, limited dose–
response data, incomplete adjustment for baseline consumption, questionable accuracy of the lifetime
smoking history data in case-control studies, and bias in cohort studies if reducers are likelier than
non-reducers to quit during follow-up. Also, the variable deﬁnitions of reduction make meta-analysis
problematic. Though the results suggest some beneﬁts of smoking reduction, more evidence is needed.
 2013 The Author. Published by Elsevier Inc. Open access under CC BY license. 1. Introduction
Many publications quantify risk of smoking-related diseases in
relation to amount smoked (e.g. International Agency for Research
on Cancer, 2004; US Surgeon General, 2004) and time since smok-
ing cessation (e.g. International Agency for Research on Cancer,
2007; Lee et al., 2012a). However, the literature relating risk to
reduction in consumption is much sparser. Most epidemiological
studies base their results on amount smoked determined only at
one time point, and many prospective studies only record smoking
habits at baseline.
Three previous reviews have considered the issue of reduction
in amount smoked. The ﬁrst (Hughes, 2000) was mainly concerned
with whether smokers can maintain reduced smoking, the extentof compensation occurring following a reduction, and whether
reduction promotes or undermines cessation. The author stated
that the question ‘‘will reduced smoking decrease the risk of smok-
ing related diseases?’’ had never been tested directly.
The same author contributed to a later review (Hughes and Car-
penter, 2006) which identiﬁed 19 studies relating reduction to sub-
sequent cessation and 10 to disease risk. While 16 of the 19
cessation studies found reduction was associated with greater fu-
ture cessation, the authors considered the evidence from the trials
of disease risk to be ‘‘conﬂicting’’, and concluded that ‘‘whether
smoking reduction decreases the risks of smoking-related diseases
has not been adequately tested’’. Interestingly, some cited studies
on risk reduction were published before 2000, contradicting the
earlier statement (Hughes, 2000).
The ﬁnal review (Pisinger and Godtfredsen, 2007) was entitled
‘‘Is there a health beneﬁt of reduced tobacco consumption? A sys-
tematic review’’. The authors identiﬁed 31 publications from 25
studies relating to various endpoints, concluding that: ‘‘the limited
data suggest that a substantial reduction in smoking improves sev-
eral cardiovascular risk factors and respiratory symptoms. In addi-
tion, smoking reduction is associated with a 25% decline in
biomarkers and incidence of lung cancer and a small, mostly non-
signiﬁcant, increase in birth weight. There seem to be no substan-
tial beneﬁcial effects on lung function. The evidence on other
health effects and mortality is too limited to draw conclusions’’.
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reduction on four major endpoints – lung cancer, chronic obstruc-
tive pulmonary disease (COPD), cardiovascular disease (CVD) and
decline in forced expiratory volume in 1 s (FEV1).2. Materials and methods
Relevant papers were sought initially from in-house databases
on smoking and COPD, quitting and FEV1 decline, and smoking
and lung cancer, which considered papers published up to, respec-
tively, 2006, June 2010, and 1999. Each database had led to a pub-
lication (COPD: Forey et al., 2011; FEV1: Lee and Fry, 2010; lung
cancer: Lee et al., 2012a) and had recorded which studies provided
results relating to smoking reduction. For lung cancer, COPD and
CVD, these papers were supplemented by Medline searches in Sep-
tember 2012 using the MESH terms ‘‘lung neoplasms’’, ‘‘pulmonary
disease, chronic obstructive’’ or ‘‘cardiovascular disease’’ in con-
junction with the MESH term ‘‘smoking’’ and occurrences of the
terms ‘‘chang’’, ‘‘reduct’’, ‘‘reduci’’, ‘‘reduce’’, ‘‘modif’’, ‘‘declin’’,
‘‘less’’, ‘‘lower’’, ‘‘decreas’’ or ‘‘fewer’’ in the title or abstract.
Additional papers were sought from references cited in reviews
(Hughes and Carpenter, 2006; Pisinger and Godtfredsen, 2007)
and in papers obtained.
Papers were grouped by the studies they gave results for. For
each study, details of study characteristics were extracted, includ-
ing design, location, timing of interview(s), number of subjects,
sexes and age groups considered, exclusion criteria, and potential
confounding variables adjusted for. Further details included length
of follow-up and endpoints considered for cohort studies, and case
and control deﬁnition and matching factors for case-control
studies.
For each disease endpoint, relative risks (RRs) or odds ratios
(ORs) and their 95% conﬁdence intervals (CIs) were extracted com-
paring cigarette smokers who reduced amount smoked (‘‘reduc-
ers’’) and those continuing to smoke at the same level (‘‘non-
reducers’’), the deﬁnition of reduction being noted. Where appro-
priate, RRs or ORs were combined over sex or over separate levels
of reduction (Gardner and Altman, 1989; Hamling et al., 2008) to
produce an overall estimate per study. These estimates were then
combined over study using random-effects meta-analysis (Fleiss
and Gross, 1991).
Estimates of FEV1 decline (ml/year) and SE were extracted sep-
arately for reducers and non-reducers, and used to estimate the
difference and its SE. The SE was estimated approximately if
unavailable, assuming the SD of an individual subject decline is
50 ml/year (Lee and Fry, 2010).3. Results
3.1. Publications and studies
Twenty-six apparently relevant publications were identiﬁed,
nine considered in the latest review (Pisinger and Godtfredsen,
2007). Four are not considered in the subsequent tables and anal-
yses. The ﬁrst (Pohlabeln et al., 1997) presented results from a lung
cancer case-control study which demonstrated substantially in-
creased risks, compared to those who continued smoking, in those
changing smoking habits up to 1 year before interview. Although
84% of the cases who changed had reduced, the results were con-
sistent with many reducing due to illness, and provided no true in-
sight into effects of reduction. The second rejected study (Alderson
et al., 1985), a hospital case-control study of various diseases, re-
ported that ‘‘for lung cancer and ischaemic heart disease, change
in number of cigarettes smoked was not related to risk. Risk of
chronic bronchitis was higher in those who recently reduced thenumber of cigarettes smoked’’. However, risk estimates were not
reported, even in a more detailed report (Alderson et al., 1986).
The third (Higgins et al., 1982) reported results from a follow-up
study relating obstructive airways disease incidence to various fac-
tors including change in consumption. However the analyses were
not restricted to continuing smokers, and the estimated advantage
of a reduction may have been mainly due to quitting. The ﬁnal re-
jected paper (Ferris et al., 1973) described results from a follow-up
study in which rates of chronic nonspeciﬁc respiratory disease in
1967 in those who smoked 25+ cigs/day in 1961 were compared
between those who maintained or reduced their consumption.
These analyses, based on only 15 reducers, are uninterpretable as
not being restricted to those disease-free in 1961.
The remaining publications could be divided into three groups
of studies; six cohort studies reporting results for one or more rel-
evant diseases, three case-control studies of lung cancer, and ﬁve
follow-up studies reporting results for changes in FEV1. One of
the FEV1 studies (Ferris et al., 1976) also presented results for
chronic nonspeciﬁc respiratory disease, but these were ignored,
as they suffered from the same weaknesses noted above for the
earlier follow-up (Ferris et al., 1973).
3.2. The cohort studies
Characteristics of the cohort studies are summarized in Table 1.
Three were conducted in Scandinavia (one each in Denmark, Fin-
land and Norway), two in Israel, and one in Korea. The studies were
of healthy populations except for that in Israel of survival in AMI
patients. Apart from the studies of Korean male civil servants
and Israeli working men, all studies were of both sexes. Each study
involved an initial survey, a second survey carried out up to
13 years later, and a subsequent follow-up period. The Korean
study involved over 475,000 subjects, the studies in Scandinavia
19,423–51,210, with the studies in Israel much smaller. The stud-
ies in Denmark, Norway and Korea provided results for the most
endpoints. All studies presented results adjusted for age and,
where relevant, sex, but adjustment for duration of smoking (one
study), amount smoked initially (two studies), and other risk fac-
tors (ﬁve studies) was less complete.
3.3. Lung cancer
Three case-control studies (see Table 2) and three cohort studies
estimated change in lung cancer risk after reducing consumption.
The case-control studies, conducted in Western Europe, USA
and France, were carried out in hospitals between 1969 and
1984. Each involved at least 1000 histologically conﬁrmed lung
cancer cases, and a larger number of control patients with diseases
unrelated to tobacco, matched to the cases on age and sex, and
sometimes other variables. There is some overlap between cases
in the West European and French studies. All three studies were
conducted in both sexes, but only results for males were reported
in the West European and French studies. All these studies ad-
justed for age and sex except for the West European case-control
study, where results taking the matching into account were re-
ported to parallel closely those from the simpler analysis. The stud-
ies varied in which other factors were adjusted for.
The three cohort studies reporting results for lung cancer were
conducted in Denmark, Norway and Korea. Though the Scandina-
vian studies involved fewer subjects than did the Korean study,
they involved a longer follow-up period.
Results relating to reduction in consumption are summarized in
Table 3, and involve numbers of cases in reducers varying from 595
(West Europe) to 12 (Norway). All RR/OR estimates are below 1.0,
except for the OR of 1.1 for a 1–25% reduction in cigarette con-
sumption in the French study, where the 95% CI of 0.4–3.0 was
Table 1
Cohort studies of smoking reduction and disease risk.
Study Denmark, Copenhagen Norway, three counties Korea, civil servants
Reference(s) Godtfredsen et al. (2001) (2002b,a) (2003) (2005) (2006) Tverdal and Bjartveit (2006) Song et al. (2008), Song and Cho
(2008)
First survey 1964–1981 1974–1978 1990
Second survey 5–10 years later 3–13 years later 1992
Sex M + F M + F M
Age at baseline 20–93 20–49 30–58
Major exclusionsa Varies by disease analyzedb Pipe/cigar smoking, previous
indication of CVDc
Had relevant diseases before
baseline
Follow up Varies between 1997 and 2003 by diseased to 2003 to 2001 (CVD) to 2003 (cancer)
Sample sizee P19,423 51,210 P475,734
Endpointsf COPD hospitalization; CHD, AMI and LC incidence; CVD, RD, TRC
and total mortality
CVD, IHD, LC, TRC and total mortality AMI, LC, STRg, TC, and TRC
incidence
Potential confounding variables adjusted for
1. Duration of
smoking
Yes No No
2. Amount smoked
initially
No No No
3. Age, sex Yes Yes Yesh
4. Othersi Yes Yes Yes
Study Israel, AMI survival Finland, Twins Israel, working men
Reference(s) Gerber et al. (2009) Hukkinen et al. (2009) Gerber et al. (2012)
First survey 1992–1993j 1975 1963
Second survey Up to 5 years laterj 1981 1965
Sex M + F M + F M
Age at baseline 665 17+ 40+
Major exclusionsc None stated (all subjects had ﬁrst AMI) No CB at baseline None stated
Follow up to 2005 No further follow-up to 2005 (all deaths)
to 1997 (cause-speciﬁc)
Sample sizef 1521 21,609 4633
Endpointsg Total mortality CB incidence CVD, non-CVD and total mortality
Potential confounding variables adjusted for
1. Duration of smoking No No No
2. Amount smoked initially Yes No Yes
3. Age, sex Yes Yes Yesh
4. Othersj Yes No Yes
a All the analyses considered are restricted to those who were examined at both the ﬁrst and second surveys, and reported smoking on both occasions.
b Exclusions varied in the publications providing relevant results – Glostrup Population Study 1914 cohort from 1964 (Godtfredsen et al., 2002a), prior hospital admission
for COPD (Godtfredsen et al., 2002b), prior hospital admission for AMI (Godtfredsen et al., 2003) and none stated (Godtfredsen et al., 2005).
c Previous indication of CVD is described as those with a history at the last examination of AMI, angina, stroke, diabetes, atherosclerosis of the legs, treated hypertension,
use of glyceryl nitrate, and symptoms indicative of angina or atherosclerosis obliterans.
d 1997 for cause-speciﬁc mortality and 2000 for all cause mortality (Godtfredsen et al., 2002a); 2003 for lung cancer (Godtfredsen et al., 2005); 1998 for COPD (Godtfredsen
et al., 2002b) and AMI (Godtfredsen et al., 2003).
e Numbers shown vary according to analysis in some studies.
f Abbreviations used: AMI = acute myocardial infarction, CHD = coronary heart disease, COPD = chronic obstructive pulmonary disease, CVD = cardiovascular disease,
IHD = ischaemic heart disease, LC = lung cancer, RD = respiratory disease, STR = stroke, TC = total cancer, TRC = tobacco related cancer.
g Results also available by subtype of stroke.
h Only age as only males were studied.
i As described in later tables.
j First survey conducted approximately 1 week after AMI, subsequent surveys were conducted 3–6 months, 1–2 years, and 5 years after AMI.
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Denmark and Korea studies, though in the US study this is not evi-
dent in females.
Combining results over study is not straightforward due to var-
iability in deﬁnition of reduction, and overlap of cases between the
West European and the French studies. However, based on the
underlined RR estimates in Table 3, the combined estimate of
0.81 (95% CI 0.74–0.88) shows a clear reduction, with no evidence
of heterogeneity. This estimate is based on all those reducing. An
alternative estimate of 0.78 (0.66–0.92) based on the greatest de-
gree of reduction for which results were available (i.e. the results
for P50% reduction in the West European and the French studies,
the heavy to light result for the Korean study, and the underlined
results for the other studies) conﬁrms the overall evidence of a
lower risk associated with cutting down. Again, there was no sig-
niﬁcant heterogeneity (p > 0.1). Only three studies (Western Eur-
ope, France, Korea) provide evidence on variation in risk by
extent of cutting down, but none show any signiﬁcant trend.Some papers present additional results (e.g. by time of decrease
in the West European study, by reduction over three screenings in
the Norway study, and by omission of events in the ﬁrst 2 years of
follow-up of the Korean study), but these do not materially affect
the overall assessment.
While our concern is with effects of reducing consumption, it is
notable that all three case-control studies reported signiﬁcant in-
creases in risk associated with increasing consumption. The reports
on the cohort studies restricted attention to cutting down.
3.4. Cardiovascular disease
Four cohort studies, in Denmark, Norway, Korea and Israel
(working men), provide results for CVD. They relate to various end-
points, including acute myocardial infarction (AMI), coronary heart
disease (CHD), ischaemic heart disease (IHD) and stroke (STR), as
well as CVD, and are summarized in Table 4. All are adjusted for
various risk factors. The studies in Denmark, Norway or Korea give
Table 2
Case-control studies of smoking reduction and lung cancer.
Study Western Europe, ﬁve countries US, nine cities France
Reference(s) Lubin et al. (1984), Lubin (1984) Augustine et al. (1989) Benhamou et al. (1989)
Timing 1976–1980 1969–1984 1976–1980
Sex M + Fa M + F M + Fa
Age No restriction No restriction No restriction
Cases Histologically conﬁrmed cases Histologically conﬁrmed cases Histologically conﬁrmed cases
Controls Hospital patients with diseases
unrelated to tobacco
Hospital patients with diseases unrelated to
tobacco
Hospital patients with diseases unrelated to tobacco
Matching factors Age, sex, centre, type of hospital
accommodation
Age, sex Age, sex, hospital, interviewer
Selection criteria for
analysis
Smoked cigarettes regularly at some
time
Current cigarette smokers switching from
non ﬁlter to ﬁlter
Case control pairs both of whom had at some time
smoked only cigarettesb
Sample size
analyzed
7,182 cases
11,006 controls
1,242 cases
2300 controls
1,027 cases
1481 controls
Potential confounding variables adjusted for
1. Duration of
smoking
Yes Yes Yes
2. Amount smoked
initially
No Yes Yes
3. Age, sex Noc Yesd Yese
4. Others No No No
a The study involved both sexes, but only data for males were analyzed.
b Two percent of smokers who had increased and then reduced consumption (or vice versa) were excluded.
c An analysis taking into account the matching factors was also conducted, but its results closely paralleled those from the simpler analysis reported.
d Adjustment was for age of switch from non ﬁlter to ﬁlter; results were separately reported by sex.
e Only age as only males were studied.
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consistent tendency for a risk reduction associated with cutting
down. However, the study in Israel did report a signiﬁcant reduc-
tion, with the RR 0.77 (95% CI 0.66–0.94). Using the ﬁve underlined
estimates in Table 4, which represent the broadest disease deﬁni-
tions available, the combined RR is 0.93 (95% CI 0.84–1.03), with
some evidence of heterogeneity (0.05 < p < 0.1).
3.5. Chronic obstructive pulmonary disease and related endpoints
Two cohort studies report results for COPD or related endpoints
(see Table 5). The Danish study shows no risk reduction associated
with cutting down for either hospital admissions from COPD or
mortality from respiratory disease. In contrast, the study of Finnish
twins reported a marked reduction (RR 0.38, 95% CI 0.21–0.67) in
incidence of CB (deﬁned as cough and phlegm for at least three
successive months a year) associated with cutting down. However,
note that the study design did not exclude the possibility that the
reduction occurred following CB onset.
3.6. All-cause mortality and other endpoints
Although the searches aimed to detect studies reporting results
for lung cancer, CVD and COPD, some cohort studies identiﬁed con-
sidered other endpoints (Table 6).
Four studies reported total mortality results. Though the two
studies in Scandinavia found no evidence of an effect of reducing
consumption, both Israel studies reported a signiﬁcant (p < 0.05)
risk reduction. Overall, the RR is estimated at 0.92 (95% CI
0.85–1.01), with no heterogeneity, consistent with some beneﬁt
of reduction.
The cohort studies presenting lung cancer results also gave
results for all tobacco-related cancer (deﬁned in the footnotes to
Table 6). Each study reported an estimated RR non-signiﬁcantly
less than 1.0. From the three underlined estimates in Table 6, the
combined RR is 0.95 (0.88–1.02), with no heterogeneity (p > 0.1).
Given the relatively clear results for lung cancer, and since lung
cancer is a major contributor to smoking-related cancer, these re-
sults provide no indication that reducing consumption reduces riskof other smoking-related cancers. Results for speciﬁc tobacco-re-
lated cancers other than lung are unavailable.
The study of working men in Israel, which reported signiﬁcant
effects of smoking reduction on CVD and on total mortality, found
no effect on non-CVD mortality, with a RR of 0.98 (95% CI 0.87–
1.10).3.7. Lung function
Table 7 summarizes characteristics of the ﬁve cohort studies
relating change in lung function to change in amount smoked.
Two were conducted in Europe (France, Denmark), two in the
USA (New Hampshire, Hawaii) and one (the Lung Health Study)
in 10 centres in USA and Canada. The Lung Health Study was of
smokers with mild-to-moderate COPD, others being general popu-
lation studies. The studies in France and in Hawaii were of males,
the others being of both sexes. The ﬁve studies, which started be-
tween 1967 and 1986, all involved changes in FEV1 and smoking
habits determined at two time points, varying from 1 year apart
(Lung Health Study) to 12 years apart (France). The studies ranged
from 556 subjects (France) to 12,698 (Denmark), though the num-
bers smoking at the beginning and end of the follow-up period
who could be included in the analyses of effects of smoking reduc-
tion were less than this. The studies varied in deﬁnitions of smok-
ing reduction and the comparison group considered.
Table 8 summarizes the results, and shows the FEV1 declines in
ml/year in non-reducers and reducers and the difference between
these two declines, along with the SE of each decline where it was
given or could be estimated. The results show little evidence of an
effect of cutting down on rate of FEV1 decline. In the studies in Ha-
waii, New Hampshire and France no effects were seen that were
close to being statistically signiﬁcant (which requires the differ-
ence to be at least about twice its SE). The same is true for older
men and women (age 55+ years) in the study in Denmark. How-
ever, there was some evidence that the rate of FEV1 decline was re-
duced in younger men and women (age <55 years) in that study,
where the decline is signiﬁcant for the sexes combined (mean
19.8 ml/year, SE 8.6 ml/year, p < 0.05).
Table 3
Summary of results relating reduction in cigarette consumption to lung cancer risk.
Sourcea Sex Basis for assessing reduction in amount smoked Reduction Cases in
reducers
RR/OR (95% CI)b
Case control studies
Western Europe Lubin
(1984)
M Most recent brand vs. maximum of earlier brands (non brand
switchers assumed to be non-reducers)
<50% 277 0.85 (0.7–1.0)c
P50% 318 0.96 (0.8–1.1)c
Any 595 0.91 (0.80–1.04)c,d
USA Augustine et al.
(1989)
M Filter vs. non-ﬁlter cigarettes (non switchers excluded) Any 106d 0.64 (0.47–0.86)e
F Any 46 0.97 (0.62–1.55)e
M + F Any 152 0.73 (0.56–0.93)d,e
France Benhamou
et al. (1989)
M Most recent vs. ﬁrst cigarette brand (non brand switchers
assumed non-reducers)
1–25% 29 1.1 (0.4–3.0)f
26–50% 42 0.8 (0.5-1.2)f
>50% 30 0.8 (0.4–1.3)f
Any 101 0.83 (0.59–1.16)d,f
Cohort studies
Denmark Godtfredsen
et al. (2005)
M + F At second and ﬁrst examinations (any tobacco)g P50% 52 0.73 (0.54–0.98)h
Norway Tverdal and
Bjartveit (2006)
M At second and ﬁrst examinations (cigarettes only)g P50% 10 0.71 (0.36–1.39)i
F P50% 2 0.51 (0.12–2.08)i
M + F P50% 12 0.66 (0.36–1.21)i
Korea Song et al.
(2008)
M At second and ﬁrst examinationsj Heavy to
moderatek
63 0.72 (0.59–0.89)l
Heavy to
lightk
95 0.63 (0.46–0.86)l
Moderate
to lightm
53 0.79 (0.64–0.98)l
By 1+
categoryn
211 0.76 (0.66–0.87)d,l
Meta-analysis
(random effects)
Of six underlined estimates 0.81 (0.74-0.88) (Heterogeneity
chisquared 5.41 on 5 d.f., p > 0.25)
a The study in Norway is of mortality; other studies are of incidence.
b Base for comparison is continuing (non-changing) smokers.
c Adjusted for duration of smoking.
d Estimated from data provided.
e Adjusted for non-ﬁlter duration, ﬁlter duration, non-ﬁlter cigs/day and age at switch from non-ﬁlter to ﬁlter cigarettes. Result for M + F additionally adjusted for sex.
f Adjusted for age, duration of smoking and daily consumption of earlier brand.
g Restricted to those who at ﬁrst examination smoked at least 15 g/day (study in Denmark) or 15 cigs/day (study in Norway).
h Adjusted for age, sex, cohort, inhalation, type of tobacco smoked and duration of smoking.
i Adjusted for age, sex, systolic and diastolic blood pressure, total cholesterol, triglycerides, physical activity, BMI, height, disability pension, sickness leave and family
history of IHD.
j Subjects were classiﬁed as heavy smokers (20 + cigs/day), moderate smokers (10–19 cigs/day) or light smokers (<10 cigs/day) at each examination.
k RR compared to continuing heavy smokers.
l Adjusted for age, height, BMI, alcohol consumption, regular exercise and salary level.
m RR compared to continuing moderate smokers.
n RR compared to all heavy or moderate smokers continuing at the same level.
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the results were given graphically, with no clear information pro-
vided on numbers of subjects with differing levels of FEV1 reduc-
tion, or on variability. They presented analyses indicating that
subjects who dramatically reduced their cigarette consumption
(by 85% or more) had a signiﬁcantly (p < 0.05) reduced rate of
FEV1 decline compared to those whose consumption stayed the
same to within ±10%. However, there was no consistent evidence
of any effect of cutting down by less than 85%.
While the overall evidence does not clearly demonstrate any ef-
fect of cutting down on the rate of decline of FEV1, the power to de-
tect effects is limited. To illustrate this, consider the data from the
Denmark study for females aged <55 years. Here there were 127
reducers and 624 continuing heavy smokers with the continuing
smokers showing a 17 ml/year decline and the reducers no decline
at all. While this result is consistent with a marked effect of cutting
down, the difference in the rate of FEV1 decline was not quite sta-
tistically signiﬁcant, the SE of the 17 ml/year difference being 9 ml/
year. If a study with 127 reducers could not detect such a marked
difference, it is unsurprising that the studies in France and New
Hampshire, with less than 30 reducers, could not do so.4. Discussion
The results described above are consistent with some health
beneﬁt of reducing cigarette consumption. This is most evident
for lung cancer where a consistent risk reduction was seen in all
six studies providing RR/OR estimates, giving a combined estimate
of 0.81 (95% CI 0.74–0.88). Non-signiﬁcant reductions are also seen
for all-cause mortality (0.92, 95% CI 0.85–1.01, n = 4), CVD (0.93,
95% CI 0.84–1.03, n = 5) and smoking-related cancer (0.95, 95% CI
0.88–1.02, n = 3). No effect on COPD or on the rate of FEV1 reduc-
tion could be established.
There are various limitations to the evidence. One limitation is
the small number of studies providing information, 14 in total and
no more than six for any single endpoint. Another is lack of power
in some studies to detect a moderate decrease in risk in reducers
relative to continuers. Thus, cases in reducers were less than 30
for many results from the Norway study, for the respiratory disease
mortality analysis from the Denmark study, and for the chronic
bronchitis incidence analysis from the Finland study. Numbers of
reducers for studying FEV1 change were also very low in the New
Hampshire and France studies.
Table 4
Summary of resultsa relating reduction in cigarette consumption to risk of cardiovascular disease.
Source Sex Diseaseb Reduction Cases in
reducers
RR (95% CI)
Denmark Godtfredsen et al.
(2002a)
M + F CVD/M P50% 85 1.01 (0.76–1.35)c
Denmark Godtfredsen et al. (2003) M + F AMI/I P50% 118 1.17 (0.91–1.50)d,e
CHD/I P50% 149 1.02 (0.83–1.24)d
Norway Tverdal and Bjartveit
(2006)
M IHD/M P50% 26 0.94 (0.63–1.41)f
CVD/M P50% 41 1.04 (0.75–1.43)f
F IHD/M P50% 3 1.13 (0.35–3.67)f
CVD/M P50% 5 0.86 (0.35–2.13)f
M + F IHD/M P50% 29 0.96 (0.65–1.41)f
CVD/M P50% 46 1.02 (0.75–1.39)f
Korea Song and Cho (2008) M AMI/I Heavy to moderateg 66 0.82 (0.65–1.03)h
Heavy to lightg 113 0.92 (0.67–1.27)h
Moderate to lighti 66 0.93 (0.76–1.15)h
By 1+ categoryj 245 0.90 (0.78–1.03)h,k
STR/I Heavy to moderateg 172 0.99 (0.86–1.14)h
Heavy to lightg 241 0.85 (0.68–1.06)h
Moderate to lighti 191 1.02 (0.90–1.16)h
By 1+ categoryj 604 1.00 (0.91–1.09)h,k
Israel Gerber et al. (2012) M CVD/M 1 or 2 categoriesl 160k 0.77 (0.66–0.94)m
Meta-analysis (random-effects Of ﬁve underlined
estimates
0.93 (0.84–1.03) (Heterogeneity chisquared 7.92 on 4 d.f.,
p < 0.1)
a All results are from cohort studies.
b Abbreviations used: AMI = acute myocardial infarction, CHD = coronary heart disease, CVD = cardiovascular disease, IHD = ischaemic heart disease, STR = stroke; /
M = mortality, /I = incidence.
c Adjusted for age, sex, cohort, BMI, education, inhalation and duration of smoking.
d Adjusted for age, sex (where relevant), cohort, systolic and diastolic blood pressure, total and high density lipoprotein cholesterol, BMI, education, alcohol, physical
activity, diabetes, inhalation and duration of smoking.
e The RR was 1.14 (0.88–1.48) if subjects with self-reported CHD at baseline were excluded.
f Adjusted for age, sex, systolic and diastolic blood pressure, total cholesterol, triglycerides, physical activity, BMI, height, disability pension, sickness leave and family
history of IHD.
g RR compared to continuing heavy (20+ cigs/day) smokers.
h Adjusted for age, height, BMI, alcohol consumption, regular exercise, salary level, blood pressure, total cholesterol, glucose and area of residence.
i RR compared to continuing moderate (10–19 cigs/day) smokers.
j RR compared to all heavy or moderate smokers continuing at the same level.
k Estimated from data provided.
l Smokers were categorized as smoking 1–10, 11–20 or 21+ cigs/day.
m Adjusted for age, socioeconomic status, smoking intensity in 1963, systolic blood pressure, blood cholesterol, body mass index, physical activity, diabetes, known CHD,
intermittent claudication and non-CVD mortality.
Table 5
Summary of resultsa relating reduction in cigarette consumption to risk of COPD and related endpoints.
Source Sex Endpoint Reduction Cases in reducers RR (95% CI)
Denmark Godtfredsen et al. (2002b) M + F COPD hospitalization P50% 82 0.93 (0.73–1.18)b
Denmark Godtfredsen et al. (2002a) M + F Respiratory disease mortality P50% 19 1.20 (0.70–2.07)c
Finland Hukkinen et al. (2009) M + F Chronic bronchitis incidence Heavy to moderate or lightd 15 0.38 (0.21–0.67)e
a All results are from cohort studies.
b Adjusted for age, sex, cohort, inhalation, type of tobacco smoked and duration of smoking; the estimate was 0.80 (0.60–1.06) if cases occurring in the ﬁrst 5 years of
follow-up were excluded.
c Adjusted for age, sex, cohort, BMI, education, inhalation and duration of smoking.
d As light smokers (<5 cigs/day) were very rare, risk in ‘‘reducers’’ has been compared with that in continuing heavy smokers (20+ cigs/day). Moderate = 5–19 cigs/day.
e Adjusted for age and sex; estimated from data provided.
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changes in cigarette consumption. It has been clearly demon-
strated, using cotinine as an objective marker of smoking, that
some smokers deny smoking on interview (Lee and Forey, 1995).
It is to be expected, therefore, that some smokers would also
understate the amount smoked. This is consistent with the obser-
vation that (except perhaps in countries where smuggling is a
major issue) average national cigarette consumption estimated
from surveys asking about amount smoked generally tends to be
lower than that derived from sales data (Forey et al., 2006–
2013). Reported changes in amount smoked are therefore also
likely to be inaccurate, though reliable evidence on this is unavail-
able, especially since there is no good biochemical marker ofamount smoked. Random errors in changes in consumption would
lead to underestimation of the true strength of the relationship
between disease risk and cutting down. However, errors may not
be random, especially where subjects at the ﬁrst interview are
advised to cut down their consumption, and may overstate any
reduction at the second interview.
The smoking data from the lung cancer case-control studies
pose special problems as being based on lifetime smoking histo-
ries, which are of questionable accuracy due to problems of recall.
The study in nine US cities was unusual, as the analyses based on it
were limited to subjects switching from non-ﬁlter to ﬁlter
cigarettes, with a reducer deﬁned as someone reporting smoking
fewer cigarettes per day when smoking ﬁlter than when smoking
Table 6
Summary of resultsa relating reduction in cigarette consumption to risk of all-cause mortality and other endpoints.
Source Sex Reduction Cases in
reducers
RR(95% CI)
All-cause mortality
Denmark Godtfredsen et al. (2002a) M + F P50% 312 1.02 (0.89–1.17)b
Norway Tverdal and Bjartveit (2006) M P50% 103 0.99 (0.80–1.22)c
F P50% 27 1.11 (0.74–1.67)c
M + F P50% 130 1.02 (0.84–1.22)c
Israel, AMI Gerber et al. (2009) M + F Per 5 cigs/day (115)d 0.89 (0.81–0.97)e
Israel, Working men Gerber et al.
(2012)
M 1 or 2 categoriesf 470g 0.85 (0.77–0.95)h
Meta-analysis (random effects) Of four underlined estimates 0.92 (0.85–1.01) (Heterogeneity chisquared 5.96 on 3 d.f.,
p > 0.11)
Smoking-related cancer
Denmark Godtfredsen et al. (2002a)i M + F P50% 46 0.91 (0.63–1.31)b
Norway Tverdal and Bjartveit (2006)j M P50% 19 0.72 (0.45–1.18)e
F P50% 8 1.40 (0.68–2.90)e
M + F P50% 27 0.86 (0.57–1.28)e
Korea Song et al. (2008)k M Heavy to moderatel 394 0.91 (0.82–1.02)m
Heavy to lightl 610 0.99 (0.85–1.16)m
Moderate to lightn 455 0.91 (0.82–1.02)m
By 1+ categoryo 1459 0.95 (0.88–1.02)m,g
Meta-analysis (random effects) Of three underlined
estimates
0.95 (0.88–1.02) (Heterogeneity chisquared 0.27 on 2 d.f., p > 0.5)
Non-CVD mortality
Israel, working men Gerber et al. (2012) M 1 or 2 categoriesf 330g 0.98 (0.87–1.10)p
a All results are from cohort studies; the study in Korea is of incidence, other studies are of mortality.
b Adjusted for age, sex, cohort, BMI, education, inhalation and duration of smoking.
c Adjusted for age, sex (where relevant), systolic and diastolic blood pressure, total cholesterol, triglycerides, physical activity, BMI, height, disability pension, sickness leave
and family history of IHD.
d There were 115 deaths in persistent smokers; the number reducing their daily consumption is not given.
e Adjusted for ‘‘baseline characteristics (including SES measures, traditional risk factors, AMI characteristics and severity indices, and co-interactions) and pre-AMI
intensity’’.
f Smokers were categorized as smoking 1–10, 11–20 or 21+ cigs/day.
g Estimated from data provided.
h Adjusted for age, socioeconomic status, smoking intensity in 1963, systolic blood pressure, blood cholesterol, body mass index, physical activity, diabetes, known CHD and
intermittent claudication.
i Tobacco-related cancers were deﬁned as cancers of the respiratory tract, including lung cancer and cancers of the upper digestive tract, including cancer of the pancreas,
kidney and urinary bladder (see Godtfredsen et al., 2002a for ICD codes).
j Tobacco-related cancers were deﬁned as cancers of the lip, oral cavity and pharynx; nose and nasal sinuses; larynx, trachea, bronchus and lung; oesophagus; stomach;
pancreas; liver; kidney and renal pelvis; bladder and ureter; and myeloid leukaemia (see Tverdal and Bjartveit, 2006 for ICD codes).
k Tobacco-related cancers were deﬁned as cancers of the lip, oral cavity and pharynx; oesophagus; stomach; pancreas; larynx; trachea; lung and bronchus; urinary bladder;
kidney and urinary tract; and myeloid leukaemia (see Song et al., 2008 for ICD codes).
l RR compared to continuing heavy smokers.
m Adjusted for age, height, BMI, alcohol consumption, regular exercise and salary level.
n RR compared to continuing moderate smokers.
o RR compared to all heavy or moderate smokers continuing at the same level.
p Adjusted for age, socioeconomic status, smoking intensity in 1963, systolic blood pressure, blood cholesterol, body mass index, physical activity, diabetes, known CHD,
intermittent claudication and CVD mortality.
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amount smoked by comparing the daily consumption of the most
recent brand smoked with the maximum consumption of earlier
brands. This is imprecise, as only up to four brands were recorded,
with changes in consumption in smokers continuing on the same
brand not recorded. The same weaknesses apply to the France
study, part of the study in West Europe. Here the comparison
was between the ﬁrst and most recent brand.
Different problems apply to the cohort studies, many of which
involved long follow-up periods, with no further smoking data col-
lected after the initial interviews. Subjects reporting a reduction
from 25 to 10 cigs/day between the two interviews may, during
the follow-up, have continued to smoke 10 cigs/day, reverted to
their original consumption, reduced further, or even quit smoking.
A lower risk in those classiﬁed as reducers may not only reﬂect a
direct effect of cutting down, but also a tendency for reducers to
be likelier to quit later than those with a steady consumption over
the two interviews. While some results from the Norway study areavailable on subjects who attended for three, rather than two
screenings, allowing this problem to be addressed, the possibility
of quitting as a biasing factor remains.
Other limitations include variation between-study in methods
used to quantify reduction in consumption, making overall assess-
ment problematic. Ideally, one would like to estimate the risk
reduction associated with cutting down for a deﬁned period by a
deﬁned amount. For quitting smoking, risk reductions by time quit
are often reported (International Agency for Research on Cancer,
2007), and have recently been meta-analysed for heart disease
(Lee et al., 2012b) and lung cancer (Fry et al., 2013). Similar results
for a deﬁned reduction in amount smoked would be of interest, but
none of the studies present results by time cut down, and the data
by extent of reduction are too limited and lacking in power to al-
low clear conclusions.
Reverse causation is another problem. This is well illustrated for
lung cancer, where short-term cutting down was shown to be asso-
ciated with a marked risk increase (Pohlabeln et al., 1997). While
Table 7
Studies of smoking reduction and changes in FEV1.
Study USA, New Hampshire France, Paris Denmark,
Copenhagen
USA, Hawaii US and Canada, 10 centres
Reference(s) Ferris et al. (1976) Kauffmann et al. (1979b,a) Lange et al. (1989) Burchﬁel et al. (1995) Simmons et al. (2005)
First survey 1967 1960–61 1976–78 1965–68 1986–1989a
Further surveys 1973 1972–73 1981–83 1968–70,
1971–75
1 year laterb
Sex M + F M M + F M M + F
Age at baseline Mainly 25+ 30–54 20+ 45–68 35–60
Sample size 1201 P556c 12698d 4451 5887e,f
Deﬁnition of smoking reduction 25+ to 1–24 cigs/day >15 to 615 g/day 15+ to <15 cigs/day Any decrease >10%
Comparison group (non-reducers) Continuing 25+ Continuing >15 Continuing 15+ No change Change 6 ±10%
Variability of estimates given No No Yes Yes Yes
a This study, the Lung Health Study, was described Anthonisen et al. (1994) as being conducted from October 1986 to April 1994, and involving intervention and a 5 years
maintenance program; so presumably started in the differing centres from 1986 to 1989.
b The analyses presented only involved FEV1 change over 1 year.
c 556 men according to Kauffmann et al. (1979b) and 575 according to Kauffmann et al. (1979a).
d The analyses related to 7764 men and women without a history of asthma who had not smoked tobacco other than cigarettes and who had not quit less than a year before
the second interview.
e This intervention study concerned smokers of 10+ cigs/day with mild to moderate COPD.
f The analyses related to 1980 subjects who did not quit in the ﬁrst year of the study.
Table 8
Summary of results relating reduction in cigarette consumption to changes in FEV1.
Source Sex (Age) Smoking reduction Number of reducers FEV1 decline (SE) in ml/yeara
Non-reducersb Reducers Difference
USA, New Hampshire Ferris et al. (1976)c M 25+ cigs/day to 1–24 cigs/day 22 6.7 (5.9) 20.0 (10.7) +13.3 (12.2)
F 18 1.7 (8.5) 10.0 (11.8) +8.3 (14.5)
France Kauffmann et al. (1979a) M >15 to 615 g/day 28 51 (4.8) 52 (9.4) +1 (10.6)
France Kauffmann et al. (1979b) M 27 51 (4.8) 48 (9.6) 3 (10.8)
Denmark Lange et al. (1989) M (<55) 15+ to <15 cigs/day 70 14 (7) 12 (15) 26 (17)
(55+) 70 21 (10) 18 (14) 3 (17)
F (<55) 127 17 (5) 0 (8) 17 (9)
(55+) 59 19 (6) 18 (10) 1 (12)
USA, Hawaii Burchﬁel et al. (1995) M Any decrease 304 33.0 (1.9) 32.6 (2.5) 0.4 (3.1)
Lung Health Study Simmons et al. (2005)d M + F 10–35% reduction 970e 80 70 10
35–65% reduction 80 0
65–85% reduction 100 +20
>85% reduction 39 10 90
a SE not available for some studies, but estimated approximately, assuming that the SD of an individual subject decline is 50 ml/year, consistent with other evidence (Lee
and Fry, 2010).
b See deﬁnition in Table 7.
c FEV1 change estimated from FEV1 values at the two time points divided by 6, the number of years of follow-up.
d Data were estimated approximately from a graph showing FEV1 declines for differing % changes in cigarette consumption. Differences in decline are estimated by
comparison with subjects who changed consumption by up to ±10%.
e Total numbers of reducers – numbers by level of reduction only given for >85% reduction.
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ity analyses omitting the ﬁrst few years of follow-up to try to ex-
clude this possibility, it is unclear how reverse causation might
have affected the case-control studies, as none of the source papers
report analyses omitting smoking history for the year or so before
lung cancer diagnosis. Reverse causation is particularly important
in the Finnish Twin Study analyses, which restricted attention to
those without CB at baseline and compared those continuing to
smoke 20+ cigs/day and those reducing to 5–19 cigs/day, as the
study design did not distinguish those who cut down and conse-
quently reduced their subsequent risk of CB, and those who got
CB and consequently cut down.
Adjustment for non-smoking confounding variables has been
found to have little effect on RRs for smoking (Thun et al., 2000),
so is unlikely to be important here. More important is possible bias
by other smoking variables. Comparison between reducers and
continuers may clearly be biased if the reducers had initially
smoked a different amount or for a different length of time. While
duration of smoking has been adjusted for in the case-controlstudies and also in the Denmark cohort study, it has not been in
other cohort studies. Analyses were adjusted for daily consump-
tion of non-ﬁlter cigarettes in the USA case-control study, for daily
consumption of the ﬁrst brand in the France case-control study,
and for pre-AMI consumption in the Israel cohort study, but other
studies apparently failed to take into account amount smoked be-
fore cutting down, despite some cohort studies noting differences
in consumption at ﬁrst interview between reducers and
continuers.
Given the strong evidence of a dose-related increase in risk of
smoking-related diseases to amount smoked (International Agency
for Research on Cancer, 2004; US Surgeon General, 2004), given the
evidence that a reduction in dose to zero (quitting) reduces risk
(International Agency for Research on Cancer, 2007; Lee et al.,
2012a,b; Fry et al., 2013), and given that dose-reduction by switch-
ing to lower tar ﬁlter cigarettes also reduces risk (Lee, 2001; Lee
and Sanders, 2004), it is plausible that reducing consumption
would reduce risk. While our ﬁndings are suggestive of some risk
reduction, particularly for lung cancer, the limitations referred to
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strated, and that more evidence is needed. Additional evidence
could be obtained from cohort studies recording smoking habits
at regular intervals, such as the Nurses Health Study, which col-
lected data biennially. Though results for smoking reduction have
never been reported, it is interesting to note that a recent publica-
tion (Kenﬁeld et al., 2010) from this study reported a stronger rela-
tionship of smoking to mortality using updated smoking status
than when using only baseline smoking status. If risks are higher
in those consistently reporting smoking on multiple occasions,
one might expect them to be higher still in those consistently
reporting heavy smoking, and lower in those who initially smoke
heavily, and then cut down.5. Conclusion
There is signiﬁcant evidence that cigarette smokers who reduce
their consumption have a lower risk of lung cancer and all-cause
mortality than those who do not, but reductions in risk of CVD
and smoking-related cancer associated with cutting down ciga-
rette consumption are not clearly demonstrated. Nor is an effect
of cutting down clearly established for COPD or on the rate of
FEV1 reduction.
Establishment of a clear relationship is affected by the limited
number of studies providing relevant results, small numbers of
cases in reducers in some studies, limited dose–response data,
incomplete adjustment for baseline consumption, and the varying
deﬁnitions of reduction used. Interpretation is affected by the
likely inaccuracy of lifetime smoking history data collected in
case-control studies, and possibilities of bias in cohort studies if
reducers are more likely than continuers to quit during follow-up.
To obtain better evidence on effects of cutting down consump-
tion on the risk of smoking-related disease more evidence is
needed, particularly from large cohort studies which collect data
at regular intervals on amount smoked.6. Conﬂict of interest statement
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